23 March 2011 Madeleine Pearce Chair: SAMED Regulatory Committee

Slides:



Advertisements
Similar presentations
Introduction of the new Canada Consumer Product Safety Act Technical Briefing January 29, 2009.
Advertisements

WHO Good Distribution Practices for Pharmaceutical Products
Country Presentation Regional Multi-stakeholder Discussion Forum on Rural ICT Development Bangkok, Thailand, 4 July 2011 Rural ICT Policy Advocacy, Knowledge.
Health and Safety Executive Health and Safety Executive Extending Cost Recovery at HSE Gordon MacDonald Director of Special Projects.
WHO update on: Guidelines for the selection of RH medicines and prequalification of priority RH medicines Medicines Policy and Standards Health Technology.
SALDA In Vitro Diagnostics in South Africa Welcome 5 November 2014 Portfolio Committee Bill
1 STRATEGIC HEALTH PLAN AND ANTICIPATED CHANGES TO MRA/MCC Dr Joey Gouws Director: Inspectorate and Law Enforcement Medicines Regulatory Authority (MRA)
Options for Regulation and the Impact of Regulation on the Marketplace 29 November 2005 Alan Kent
Getting our Acts together! Health products regulatory regimes: more than meets the eye.
Implementation - Medical Devices. Overview Act on Medical Devices – background and overview. Surveillance - Competent authority. Directive 93/42. Directive.
Introduction to Regulation
Portfolio Committee on Health BRIEFING ON THE MEDICINES AND RELATED SUBSTANCES AMENDMENT BILL Date: 3 September 2014.
National Environmental Management Act Second Amendment Bill BACKGROUND NOTES ON RATIONALE AND IMPORTANT CHANGES FEBRUARY 2004.
November  The Case for a Marketing Code of Practice  The Marketing Code of Practice Journey  The Parts to the Code  So What?  Examples & Scenarios.
The FDA Landscape AdvaMed September 2008 Judith K. Meritz
Central Asia Regional Health Security Workshop Co-organized with the Command Surgeon, US Central Command and the George C. Marshall European Center for.
Regulations Relating to Foodstuffs for Infants and Young Children (Foodstuffs, Cosmetics and Disinfectants Act, 1972) Briefing to the Portfolio Committee.
Project co-financed by European Union Project co- financed by Asean European Committee for Standardization Implementing Agency 1 Module 13 GMP Workshop.
Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.
1 SG C Regulatory Fitness and Performance Programme (REFIT) September 2014.
REPORT ON THE MINISTERIAL TASK TEAM REVIEW OF MEDICINES CONTROL COUNCIL AND RECOMMENDATIONS ON THE NEW REGULATORY AUTHORITY PRESENTATION TO HEALTH PORTFOLIO.
SALDA Presentation to the Honourable Portfolio Committee on Health National Health Act Amendment Bill B March 2012.
SAHPRA proposals Nov 2009 A GLIMPSE OF WHAT SAHPRA IS INTENDED TO BECOME KEY PROPOSALS FOR SAHPRA NOVEMBER 2009 DR NICHOLAS CRISP.
Consultative meeting Registrar of Medicines & Pharmaceutical Industry Ms Mandisa Hela Medicines Regulatory Affairs Department of Health 4 September 2008.
Presented by J F Luterek, Pr.Eng Hahn & Hahn Attorneys
Presentation to Parliamentary Portfolio Committee on Health OHSC Tuesday, 13 March 2012 Tjaart Erasmus.
Presentation to the Portfolio Committee on Water and Environmental Affairs National Environmental Management Laws Amendment Bill.
Latest in Health Law…. SAPRAA June Key pieces of legislation Health Charter & BB BEE Medicines & Related Substance Act, regulations & Code Medical.
SALDA Presentation to the Honourable Portfolio Committee on Health
1 FEEDBACK ON MCC PROJECT MEETING HELD ON 14 MAY 2010 Dr Dorcas Peta 4 JUNE 2010.
Amendment Bill 6 of 2014 Briefing to the Portfolio Committee 26 th November 2014.
DISCOVERY HEALTH COMMENTS ON THE MEDICINES AND RELATED SUBSTANCES BILL August 2008.
IPASA presentation to Portfolio Committee on Health 31 October 2014 Abeda Williams.
1 THE NURSING BILL BRIEFING BY THE NATIONAL DEPARTMENT OF HEALTH CAPE TOWN 15 NOVEMBER 2005.
Medicines and Related Substances Amendment Bill 2008 Pharmaceutical Task Group: Industry Marketing Code Steering Committee Presented by: Maureen Kirkman.
Proposal for a Regulation of the European Parliament and of the Council on medical devices and amending Directive 2001/83/EC, Regulation (EC) No 178/2002.
REVISION of IVD DIRECTIVE Regulation instead of Directive.
UPCOMING CHANGES TO IN-VITRO DIAGNOSTICS (IVDs) AND LABORATORY DEVELOPED TESTS (LDTs) REGULATIONS Moj Eram, PhD November 5, 2015.
Presented by The Health Products Association (HPA) of South Africa Honourable Members – Thank you for this opportunity. Act 101 – Draft Amendment Bill.
Portfolio Committee for Health Medicines and Related Substances Amendment Bill (06/08/08) IMSA represents Research Based Pharmaceutical Companies.
WELS Scheme Independent Review. Background WELS scheme commenced in 2005 s76 of WELS Act 2005 requires an independent review after 5 years Dr Chris Guest.
ERIC REURTS Draft SA Marketing Code. Marketing Code Steering Committee PIASA - Pharmaceutical Industry Association NAPM – National Association of Pharmaceutical.
R EGULATING THE IMPORTATION & USE OF MEDICAL DEVICES.
Design and buildTestShadowGo live Oct 15Nov 15Dec 15Jan 16Feb 16Mar 16Apr 16May 16Jun 16Jul 16Aug 16Sep 16Oct 16Nov 16Dec 16Jan 17Feb 17Mar 17Apr 17 Oct.
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
Date Insert on Master Slide Slide 1 Regulatory Framework within which patients can have safe and more convenient access to medicines Royal College of Physicians.
THE OFFICE FOR REGISTRATION OF MEDICINAL PRODUCTS, MEDICAL DEVICES AND BIOCIDAL PRODUCTS Responsibility in the handling of medical devices.
M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 1 – Free movement of goods Bilateral.
Municipal Managers’ Forum Upper Limits for Senior Manager 10 June 2016.
Burden of Disease Research Unit (BOD) Towards a National Procedure Coding Standard for South Africa Lyn Hanmer Health Informatics R&D Co-ordination (HIRD)
Frankie Wallace Supplier Engagement Lead
Update on EU regulatory developments
Industry Implementation Priorities & Challenges COM/CAMD Stakeholders meeting on the new MD and IVD Regulations 9 March, 2017 John Brennan Director.
BRIEFING BY THE NATIONAL DEPARTMENT OF HEALTH
Industry meeting with Nicholas Crisp on 27 February 2012
Unit for Medical Systems and Devices at Ministry of Health
National Department of Health
Medicines Control Council (MCC) &
Parliament and the National Budget Process
Establishing the Infrastructure for Radiation Safety Preparatory Actions and Initial Regulatory Activities.
Proposal for a Regulation on medical devices and Proposal for a Regulation on in vitro diagnostic medical devices Key Provisions and GIRP Assessment.
IMPLEMENTATION OF THE SOUTH AFRICAN LANGUAGE PRACTITIONERS COUNCIL ACT, 2014 (Act No. 8 of 2014) PRESENTED TO THE SELECT COMMITTEE ON EDUCATION & RECREATION.
TRADITIONAL HEALTH PRACTITIONERS ACT 2007 (Act No. 22 0f 2007)
1/12/2019 Amendment Bill 6D of 2014 Briefing to the Portfolio Committee of Health 04 November 2015.
Medicines Control Council (MCC) &
Patient Involvement in the Development and Safe Use of
NEW MDR Regulatory Context. NEW MDR Regulatory Context.
MEDICAL DEVICES CONTROL SYSTEM IN INDONESIA
Dr Manisha Shridhar Regional Advisor WHO-SEARO
Access to Cannabis for Medicinal and Research Purposes
Presentation transcript:

23 March 2011 Madeleine Pearce Chair: SAMED Regulatory Committee Medical Devices and Regulations: Feedback from SAMED’s Meeting with Benguela EOH 27 February 2012 23 March 2011 Madeleine Pearce Chair: SAMED Regulatory Committee

POSITION ON MEDICAL DEVICE REGULATION SAMED strongly supports a legislative and regulatory framework to control the manufacture, distribution and marketing of medical devices and in-vitro diagnostics (IVDs) to ensure that South African patients have access to products that are safe, effective and of good quality. 2

Previously…….

Act 72 of 2008 Amended the Medicines and Related Substances Control Act 101 of 1965 Introduced SAHPRA (the South African Health Products Regulatory Authority) Made provisions for the registration of medical devices and in-vitro diagnostics …….. was never brought into law

Implementation of SAHPRA SAHPRA is not likely to be implemented in 2012 Cabinet decision Dec 2011: SAHPRA will be a Schedule 3A Public Entity Medicines and Related Substances Amendment Act (Act 72 of 2008) will be returned to Parliament for an amendment to remove the definition of health product (“product”). Changing legislation takes time (>12 months) With no enabling legislation, implementation of SAHPRA cannot go ahead

Benguela Health Was brought in to handle the medicines backlog and design SAHPRA SAMED/SALDA worked on medical device regulations with BH in several workshops Jan-June 2011 Project was put on hold – priorities such as NHI

Benguela EOH Project Team Benguela Health joined EOH Continuation of work done with industry in 2011 and previous years Project secured renewed funding to complete SAHPRA project In 2012, reports to Registrar of Medicines, Mandisa Hela, who is in charge of delivering SAHPRA Legislation update means that the Project Team will not facilitate implementation of SAHPRA but will prepare everything needed to establish and run entity Target of end June 2012 to have all outstanding work completed and packaged for the Minister

Health Technology Department NDOH Sam Bakhane appointed as DDG Terry Downes collating comments from regulations pertaining to Act 101 published in July 2011 Not likely to go any further MAC _HT Advisory Panel for regulation

Meeting Benguela/Industry 27 Feb 2012 PART A (All) General feedback Act and amendments Public Entity Structure Food CAMS New Project Team Medicines EDMS eCTD Fees PART B (With core group of device industry players to pick up on the Act 72 device regulations) Devices Regulations

Prepare all required to establish and run SAHPRA Deliverable: Prepare all required to establish and run SAHPRA new establishment must improve situation, must not be ambiguous, must not be subject to corruption - medicines, medical devices, diagnostics, food, complimentary medicine, cosmetics, African traditional medicines, disinfectants Create an Operating Manual for SAHPRA

A regulations document – general principles To support the coming amendment to the Act Attempt to fix gaps in regulation before amended law is enacted Attempt to adapt medicines regulations and guidelines for medical devices/IVDs Cannot refer to international standards Tighter regulation and in detail to prevent too many changes as DOH changes policy (politicians come and go) Offences and penalties are required

Discussion Points 27 Feb 2012 SAHPRA Fees no cross subsidisation from other regulated health products categories estimated 35 line items per product group for registration/per fee payable

Discussion Points 27 Feb 2012 Labelling no special labelling for South Africa international guidelines for device/IVD labelling impact of supply if medicines labelling regime is followed medical device/IVD supply chain is different –to whom are you directing labelling

Discussion Points 27 Feb 2012 Authorised Representative Manufacturer Legal Manufacturer Distributor Agent Consider Medical Device supply chain Multiple agents, retail

Discussion Points 27 Feb 2012 Recalls Field Safety Corrective Action Considerations Role of the Regulator Role of Applicant Time frames

Discussion Points 27 Feb 2012 Combination products guideline Medicines Control Council approach vs International approach

Discussion Points 27 Feb 2012 User Defined in the National Health Act Patient? Health care practitioner? Operator? Defined in the National Health Act “user” means the person receiving treatment in a health establishment, including receiving blood or blood products, or using a health service

Documents provided by SAMED Guidelines on: Establishment Licence Product Registration Medical Device Classification Medical Device Labelling Lodging a complaint for a Medical Device/IVD Recalls and Adverse Events

Documents provided by SAMED International references provided information on: Changes to Registration Clinical Trials Vigilance Reporting Requirements Terminology differences for MDs (PIL, PI, IFU, User Manual) Product evaluations Differentiating handling of capital equipment vs other MDs Implants Custom made devices Conformance Marking Handling of Transition Period, Grandfathering Quality Management Systems Establishment vs device licence

Next Steps Meeting with core group 12 April Regulations document review Discussion on proposed fees vs service level agreements vs capacity Comments on GWP guideline due 30 March Comments on amendment to Act 101 due 15 June 2012

Questions